InChI
1S/C15H16Cl2N2O8.Na.H/c16-14(17)15(24)18-10(7-27-12(22)6-5-11(20)21)13(23)8-1-3-9(4-2-8)19(25)26;;/h1-4,10,13-14,23H,5-7H2,(H,18,24)(H,20,21);;/t10-,13-;;/m1../s1
SMILES string
[Na].O[C@@H]([C@@H](COC(=O)CCC(O)=O)NC(=O)C(Cl)Cl)c1ccc(cc1)N(=O)=O
InChI key
RJOAHMNSYANTPN-OWVUFADGSA-N
grade
pharmaceutical primary standard
API family
chloramphenicol
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Chloramphenicol sodium succinate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Carc. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Participation of macrophages in chloramphenicol-potentiated carrageenin-induced peritonitis in rats.
J R Moraes et al.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 26(5), 497-507 (1993-05-01)
1. We investigated the possible potentiating effect of chloramphenicol succinate (30 mg/kg, every 12 h for 4 days, ip) on the response of polymorphonuclear neutrophils to carrageenin (150 micrograms, ip) or dextran (100 micrograms, ip) in the peritoneal cavity of
Javier A Sala-Mercado et al.
Circulation, 122(11 Suppl), S179-S184 (2010-09-21)
Emerging evidence suggests that "adaptive" induction of autophagy (the cellular process responsible for the degradation and recycling of proteins and organelles) may confer a cardioprotective phenotype and represent a novel strategy to limit ischemia-reperfusion injury. Our aim was to test
D E Holt et al.
Human & experimental toxicology, 17(1), 8-17 (1998-03-10)
1. Chloramphenicol continues to be widely used in many parts of the world despite its known haematotoxicity. Until now, elucidation of the mechanisms involved and any attempt at amelioration of the toxic effects have been hampered by the lack of
L Tammaro et al.
International journal of antimicrobial agents, 29(4), 417-423 (2007-02-17)
New polymeric composite materials containing a nanohybrid to be used for the controlled release of an antibiotic molecule, chloramphenicol succinate, have been formulated, prepared and characterised. The nanohybrid consists of a layered double hydroxide of Mg-Al hydrotalcite-type, in which the
Roberta A Gottlieb et al.
Autophagy, 7(4), 434-435 (2010-12-29)
Interventions that reduce infarct size in animal models have largely failed to improve outcome in patients suffering acute myocardial infarction (MI), or 'heart attack'. Our group recently reported a reduction of infarct size by chloramphenicol treatment in a porcine in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持